BOFAS News & Events

This pages lists all the latest news and upcoming events.

 

To access 'Foot Print' (the BOFAS Bulletin) please click here (members only)

 

Latest News

EFAS Lyon 2021 - Hybrid Annual Meeting

October 21-22-23 - Combined Face to Face and Virtual Meeting

The EFAS Congress Lyon 2021 will be the first hybrid congress from the European Foot and Ankle Society. 

EFAS hopes BOFAS members and others will join them in person for 3 amazing days of congress, to meet each other and exchange ideas, but in the current climate going abroad might still be difficult. EFAS would therefore like to extend the opportunity for all to be part of the congress by going HYBRID for the first time. 

Annual Meeting 2021 - Recap

The 2021 Annual Meeting is over, but click here if you missed it!

We hope you enjoyed the 2021 Virtual Annual meeting, but if you could not make it, it's available for members free of charge! Follow the link to view the programme and recordings. 

123456789

 

BOFAS Hosted Events

Courses organised by BOFAS
 

 

BOFAS Affiliated Courses

Courses by organisations with an affiliation to BOFAS
 

Other External Events / Courses

Independant courses organised by other organisations not directly affiliated with BOFAS, but which BOFAS members may find of value.
 
Karan Malhotra
/ Categories: Abstracts, 2021, Poster

DVT and Achilles tendon rupture - a better pill to swallow?

G. Scott, A. Biggs, A. Carne, M. Rogers, M. Solan

Background: The BOFAS Guidance regards Achilles rupture patients as particularly high risk for VTE. Many hospitals use 6-weeks of low molecular weight heparin (LMWH) injections which are unpleasant for patients and result in reduced compliance. An extended course of prophylaxis is advised following hip and knee arthroplasty, however Novel Oral Anti-Coagulant (NOAC) tablets are licensed. We offered Rivaroxaban to our Achilles patients as an alternative. Since this is “off-license”, we developed an information sheet and consent form. In this study we compared VTE prophylaxis outcomes in our Achilles rupture patients.

Methods: We retrospectively reviewed patients diagnosed during three different periods between 2010 and 2019. During the first patients were treated in any fracture clinic. Chemical prophylaxis was not always prescribed. In the second period patients were triaged to a Foot & Ankle clinic. VTE prophylaxis was universal but not standardised. The third period saw patients managed by one F&A surgeon using the Rivaroxaban protocol. Thromboembolic event or significant bleeding within 3 months of treatment were recorded outcomes.

Results: Two hundred and thirty patients with Achilles tendon rupture were identified. Thirty-one were excluded because they took anticoagulants already or had a DVT on initial USS. There were no secondary bleeding episodes or fatal PEs. Forty patients had no prophylaxis and 7.5% of these developed a symptomatic DVT or PE. Of the 80 patients managed with LMWH, 6.25% suffered a thromboembolic event. A total of 79 patients were given Rivaroxaban and zero suffered a DVT or PE.

Conclusion: Numbers here are small, but suggests Rivaroxaban is an appropriate alternative to LMWH. Poor compliance due to pain and bruising from injections isn't relevant with a tablet that also doesn't require any patient/family education. Rivaroxaban has led to improved VTE rates for patients with Achilles tendon rupture in our hospital with no complications.

Print
7407

Documents to download